Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens - PubMed (original) (raw)

doi: 10.1136/jnnp-2012-303807. Epub 2012 Nov 22.

Sukhvir Wright, Patrick Waters, Shakti Agrawal, Lucinda Carr, Helen Cross, Carlos De Sousa, Catherine Devile, Penny Fallon, Rajat Gupta, Tammy Hedderly, Elaine Hughes, Tim Kerr, Karine Lascelles, Jean-Pierre Lin, Sunny Philip, Keith Pohl, Prab Prabahkar, Martin Smith, Ruth Williams, Antonia Clarke, Cheryl Hemingway, Evangeline Wassmer, Angela Vincent, Ming J Lim

Affiliations

Free PMC article

Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens

Yael Hacohen et al. J Neurol Neurosurg Psychiatry. 2013 Jul.

Free PMC article

Abstract

Objective: To report the clinical and investigative features of children with a clinical diagnosis of probable autoimmune encephalopathy, both with and without antibodies to central nervous system antigens.

Method: Patients with encephalopathy plus one or more of neuropsychiatric symptoms, seizures, movement disorder or cognitive dysfunction, were identified from 111 paediatric serum samples referred from five tertiary paediatric neurology centres to Oxford for antibody testing in 2007-2010. A blinded clinical review panel identified 48 patients with a diagnosis of probable autoimmune encephalitis whose features are described. All samples were tested/retested for antibodies to N-methyl-D-aspartate receptor (NMDAR), VGKC-complex, LGI1, CASPR2 and contactin-2, GlyR, D1R, D2R, AMPAR, GABA(B)R and glutamic acid decarboxylase.

Results: Seizures (83%), behavioural change (63%), confusion (50%), movement disorder (38%) and hallucinations (25%) were common. 52% required intensive care support for seizure control or profound encephalopathy. An acute infective organism (15%) or abnormal cerebrospinal fluid (32%), EEG (70%) or MRI (37%) abnormalities were found. One 14-year-old girl had an ovarian teratoma. Serum antibodies were detected in 21/48 (44%) patients: NMDAR 13/48 (27%), VGKC-complex 7/48(15%) and GlyR 1/48(2%). Antibody negative patients shared similar clinical features to those who had specific antibodies detected. 18/34 patients (52%) who received immunotherapy made a complete recovery compared to 4/14 (28%) who were not treated; reductions in modified Rankin Scale for children scores were more common following immunotherapies. Antibody status did not appear to influence the treatment effect.

Conclusions: Our study outlines the common clinical and paraclinical features of children and adolescents with probable autoimmune encephalopathies. These patients, irrespective of positivity for the known antibody targets, appeared to benefit from immunotherapies and further antibody targets may be defined in the future.

Keywords: Amnesia; Epilepsy; Limbic System; Movement Disorders; Paediatric Neurology.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Study flow chart showing expert review and record linkage outcome. Four patients who were excluded from the study because they were not encephalopathic were positive for autoantibodies in the serum; two had VGKC-complex antibodies (one Guillain–Barré syndrome and one myositis) and two had N-methyl-D-aspartate receptor antibodies (one movement disorder, one optic neuritis). Patients with demyelinating conditions, Rasmussen encephalitis, or with neurological symptoms secondary to systemic diseases could have an autoimmune mechanism for their disorder but were excluded from this study.

Figure 2

Figure 2

Demographics of patients with autoimmune encephalopathy. (A) Age at disease onset of the 48 paediatric patients with autoimmune encephalopathy divided between antibody positive and antibody negative, male and female patients. (B) Ethnicity of the 48 paediatric patients with autoimmune encephalopathy; 24 patients (50%) were non-Caucasian: Asian (13), Black (5) and Other (6).

Figure 3

Figure 3

Outcome of all patients with autoimmune encephalopathy. The problems encountered in children at follow-up of 1–5 years (mean=24 months). Twenty patients recovered completely. Cognitive problems were still present in 23, seizures in 16, behavioural problems in 17 and two patients had additional motor problems.

Figure 4

Figure 4

Modified Rankin Scale (mRS) for children score reduction in total cohort and in the antibody positive and negative groups, stratified according to immunotherapies. A significant improvement of the mRS score between nadir and final follow-up, as measured by the χ2 test, was seen in the patients who received immunotherapies (p=0.04) (A), with a similar trend in the antibody positive (B) and antibody negative (C) groups.

Comment in

Similar articles

Cited by

References

    1. Davies E, Connolly DJ, Mordekar SR. Encephalopathy in children: an approach to assessment and management. Arch Dis Child 2012;97:452–8 - PubMed
    1. Glaser CA, Gilliam S, Schnurr D, et al. In search of encephalitis etiologies: diagnostic challenges in the California Encephalitis Project, 1998–2000. Clin Infect Dis 2003;36:731–42 - PubMed
    1. Granerod J, Cunningham R, Zuckerman M, et al. Causality in acute encephalitis: defining aetiologies. Epidemiol Infect 2010;138:783–800 - PubMed
    1. Vincent A, Bien CG, Irani SR, et al. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011;10:759–72 - PubMed
    1. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63–74 - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources